Core Viewpoint - The article discusses the recent progress of Hangzhou Deshi Biotechnology Co., Ltd. in its IPO application process in Hong Kong, positioning itself as a potential leader in the medical imaging AI sector, specifically aiming to become the first company in this field to go public [2]. Company Overview: Focused on Medical Imaging AI - Deshi Biotechnology, established in 2018 and headquartered in Hangzhou, specializes in medical imaging artificial intelligence and intelligent diagnostic software, with core technologies covering imaging algorithms and AI model training platforms [3]. - The company does not pursue a "general large model" approach but focuses on specific clinical scenarios such as hematology and cytogenetics, creating a relatively vertical AI product system tailored to real application needs in laboratories and clinics [3]. Products and Technology: Advancing to Full Automation - The main commercial products include AutoVision® and MetaSight®, which have been implemented in some medical institutions [4]. - The core product, AI AutoVision®, is designed as a fully automated, end-to-end cytogenetic analysis system, aiming to elevate the current semi-automated detection to a higher level of automation [8]. Financial Performance: Rapid Revenue Growth - Deshi Biotechnology has shown continuous revenue growth, with a significant acceleration in commercialization since 2025 [9]. - Revenue data reveals: - 2023: Revenue of 52.844 million RMB - 2024: Revenue of 70.352 million RMB, a year-on-year increase of 33.1% - For the nine months ending September 30, 2025: Revenue of 111.6 million RMB, a substantial increase of 469.8% compared to 19.588 million RMB in the same period of 2024 [12]. - Sales of AutoVision® and MetaSight® increased by 40.9% and 160.0% respectively, with an increase in average selling prices due to a higher direct sales ratio [13]. Profitability Situation - The company is still in the investment phase, with R&D expenditures and sales system development impacting short-term profitability [14]. - For the nine months ending September 30, 2025, the net loss was approximately 36.6 million RMB, a reduction from 50.8 million RMB in the same period of 2024 [19]. Observations: A Vertical AI Company - Deshi Biotechnology adopts a vertical approach focused on specific testing scenarios rather than the common narrative of general medical large models [15]. - The financial structure indicates that the company has moved beyond pure R&D and is entering a phase of commercialization and revenue growth, but the sustainability of its business model will depend on the approval and large-scale implementation of its core product, AI AutoVision® [15].

Core Insights - The article highlights the rapid growth and potential of the AI medical imaging sector, with Deshi Biotechnology Co., Ltd. (Deshi Bio) leading the field and preparing for an IPO in Hong Kong through the 18A process [1][11]. Company Overview - Deshi Bio was founded by Dr. Song Ning, who has a multidisciplinary background in computer science, life sciences, and clinical medicine, and has received significant recognition from the primary capital market [1][2]. - The company has undergone five rounds of financing since its establishment in 2016, achieving a valuation of 2.56 billion RMB [1][3]. Ownership Structure - Dr. Song holds over 50% of the voting rights, with a direct shareholding of 30.04% and control through various investment platforms [3][4]. - The company has seen dilution of shares due to external investments, but Dr. Song has strategically repurchased shares to maintain control [2][4]. Strategic Focus - Deshi Bio is divesting from low-margin businesses to concentrate on its core AI medical imaging operations, reflecting a commitment to high-value areas [5]. - The company has developed a comprehensive ecosystem for AI medical imaging, including innovative products like AutoVision® and MetaSight®, which have received multiple international certifications [7][8]. Market Potential - The AI medical imaging market in China is projected to grow at a compound annual growth rate (CAGR) of 60.2%, with the market size expected to reach 40.1 billion RMB by 2030 [6][7]. - Deshi Bio has achieved a 30.6% market share in the chromosome analysis system sector, positioning itself as a leading player in the industry [8]. Financial Performance - In 2024, Deshi Bio reported revenues of approximately 70.35 million RMB, a year-on-year increase of 33.1%, driven by the growth of its cloud service offerings [9][10]. - The company has improved its gross profit margin to 65.5%, indicating strong profitability potential within the medical device sector [9]. Future Plans - The funds raised from the IPO will be allocated to market promotion and further development of AI products, aiming to transition from an "AI tool provider" to a "full-modal medical AI infrastructure architect" [11][12].

Core Viewpoint - The article highlights the rapid growth and potential of the AI medical imaging sector, focusing on Deshi Biotechnology Co., Ltd. as a leading player preparing for an IPO in Hong Kong, with a valuation of 2.56 billion RMB after nine years of development and five rounds of financing [1][3]. Company Background - The founder, Dr. Song Ning, has a multidisciplinary background in computer science and clinical medicine, holding degrees from Central South University and Nagasaki University [2]. - Deshi Biotechnology was established in September 2016 with an initial registered capital of 1 million RMB, and has since attracted significant investment from various institutions [2][3]. Shareholding Structure - Dr. Song currently holds 30.04% of the shares directly and controls 52.06% of the voting rights through various platforms, despite facing dilution from external investments [3]. - The company has a notable shareholder list, primarily consisting of institutional investors, with a unique individual shareholder, Yang Xi, who was incentivized through a share transfer agreement [5]. Strategic Decisions - In 2020, Dr. Song repurchased shares from a previous investor to regain control, reflecting a commitment to protect the company's interests [3]. - The company plans to divest from low-margin businesses to focus on its core AI operations, indicating a strategic shift towards higher-value segments [6]. Market Potential - The AI medical imaging market in China is projected to grow at a compound annual growth rate (CAGR) of 60.2%, reaching 40.1 billion RMB by 2030 [7]. - Deshi Biotechnology has developed a comprehensive ecosystem for AI medical imaging, including innovative products like AutoVision® and MetaSight®, which have received multiple international certifications [7][9]. Financial Performance - In 2024, the company reported revenue of approximately 70.35 million RMB, a 33.1% increase year-on-year, driven by the growth of its cloud services [10]. - The gross profit margin for 2024 was 65.5%, indicating strong profitability relative to industry standards, with a significant reduction in net losses compared to the previous year [10]. Future Plans - The upcoming IPO aims to raise funds for marketing and further development of AI products, positioning the company as a leader in the global medical imaging AI landscape [12][13]. - Deshi Biotechnology is set to transition from being an "AI tool provider" to a "full-modal medical AI infrastructure architect," reflecting its ambition to lead in technological innovation and market expansion [13].